(Q44445036)

3 December 2017

Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients (English)

1 reference

3 December 2017

0 references

Jung-Ta Kao

1

1 reference

3 December 2017

Hsueh-Chou Lai

2

1 reference

3 December 2017

Shu-Mei Tsai

3

1 reference

3 December 2017

Pei-Chao Lin

4

1 reference

3 December 2017

Po-Heng Chuang

5

1 reference

3 December 2017

Cheng-Ju Yu

6

1 reference

3 December 2017

Ken-Sheng Cheng

7

1 reference

3 December 2017

Wen-Pang Su

8

1 reference

3 December 2017

Ping-Ning Hsu

9

1 reference

3 December 2017

Cheng-Yuan Peng

10

1 reference

3 December 2017

Yi-Ying Wu

11

1 reference

3 December 2017

9 January 2012

1 reference

3 December 2017

1 reference

3 December 2017

32

1 reference

3 December 2017

6

1 reference

3 December 2017

928-936

1 reference

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

3 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Immune system and hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Positive and negative regulation of the IL-27 receptor during lymphoid cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Differential effects of IL-27 on human B cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Hyperproduction of proinflammatory cytokines by WSX-1-deficient NKT cells in concanavalin A-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Understanding the pro- and anti-inflammatory properties of IL-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Potent antitumor activity of interleukin-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Antiangiogenic and antitumor activities of IL-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

The biology and therapeutic potential of interleukin 27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Cutting Edge: Role of IL-27/WSX-1 Signaling for Induction of T-Bet Through Activation of STAT1 During Initial Th1 Commitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Immunopathogenesis of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02742.X

10.1111/J.1478-3231.2011.02742.X

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference